Home › Carcinoma uroteliale (a cellule transizionali) › Massachusetts › Boston
Studi clinici su Carcinoma uroteliale (a cellule transizionali) a Boston, MA
11 studi su Carcinoma uroteliale (a cellule transizionali) cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #7, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
In reclutamentoFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
In reclutamentoStudio osservazionale
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
In reclutamentoFase 1/2
- Tufts Medical Center, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
In reclutamentoFase 3
- Massachusetts General Hospital, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
In reclutamentoFase 3
- Research Site, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
In reclutamentoStudio osservazionale
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Studi su Carcinoma uroteliale (a cellule transizionali) in altre città
- Nashville, TN23 studi
- New York City, NY22 studi
- Dallas, TX18 studi
- Edison, NJ18 studi
- Houston, TX18 studi
- Los Angeles, CA17 studi
- Queens, NY15 studi
- Chicago, IL14 studi
- Arlington, VA12 studi
- San Antonio, TX11 studi
- Austin, TX10 studi
- Orange, CA10 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.